Literature DB >> 24578491

Optimizing tolerability of TKI therapy in CML.

Andreas Hochhaus1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24578491     DOI: 10.1182/blood-2014-01-546705

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  3 in total

Review 1.  Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Authors:  Lauren Caldemeyer; Michael Dugan; John Edwards; Luke Akard
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

2.  ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations-comment.

Authors:  Leonardo Campiotti; Matteo Basilio Sutter; Elena Bolzacchini; Alessandro Squizzato
Journal:  Intern Emerg Med       Date:  2018-03-27       Impact factor: 3.397

3.  [Chronic myelogenous leukemia].

Authors:  A Hochhaus; P La Rosée; E Eigendorff; T Ernst
Journal:  Internist (Berl)       Date:  2015-04       Impact factor: 0.743

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.